Business Wire

PA-PPG

24.5.2022 14:33:14 CEST | Business Wire | Press release

Share
PPG Commits to Setting Science-Based Targets to Reduce Greenhouse Gas Emissions, Unveils 2021 ESG Report

PPG (NYSE:PPG) today announced that it has committed to setting near-term company-wide emission reductions in line with climate science through the Science Based Target initiative (SBTi), which is an organization that helps companies define their decarbonization strategy and reduce the impacts of climate change.

PPG has an existing goal to reduce GHG emissions intensity by 15% by 2025 from a 2017 baseline, achieving a 9.7% reduction in 2021. The company has long reported emissions intensity from its own operations (Scope 1 emissions) and purchased electricity, steam, heating and cooling (Scope 2 emissions) and plans to unveil its new 2030 goals over the coming months. Moving forward, PPG is prioritizing evaluating indirect emissions that are from sources outside of the organization that PPG does not own or control, including raw materials, use of sold products, and product end-of-life (Scope 3 emissions).

“In this critical moment for climate change, we are committed to further evaluating and reducing emissions throughout our value chain,” said Diane Kappas, PPG vice president, Global Sustainability. “We are working across our organization to define additional actions we can take to help prevent the earth from warming more than 1.5 degrees Celsius. Following our validation work with SBTi and an emissions analysis, we intend to announce new, aggressive 2030 goals that will define our decarbonization strategy to help protect the planet for current and future generations.”

PPG also released its 2021 Environmental, Social and Governance (ESG) Report, which details advancements in its sustainable innovations, board governance of ESG, efforts to reach its 2025 sustainability goals and further actions to support customers’ sustainability goals. The full report is available at sustainability.ppg.com .

“Sustainability is at the heart of our purpose to protect and beautify the world,” said Kappas. “Our employees’ hard work and dedication helped us meet and surpass several of our near-term 2025 goals, and we continue to look for additional ways to reduce our emissions and overall environmental impact. While we are proud of our achievements, we recognize that now is the time for further action. We look forward to unveiling science-based targets as we complete the validation process.”

The latest report highlights PPG’s environmental actions and innovations globally. Key highlights include:

  • Introduced PPG ERGOLUXE™ powder coatings, which offer first-pass transfer efficiency rates of up to 85% and the ability to reuse overspray. PPG ErgoLuxe Eco contains up to 13% recycled polyethylene terephthalate (rPET). Since 2017, PPG has used more than 6 million pounds of rPET to manufacture its coatings.
  • Launched COMEX® TOP paint by PPG, which contributes to the circular economy by incorporating recycled tires, saving more than 270,000 tires from landfills since the product was introduced in 2021. The product is intended for application on roofs and provides thermal insulation, resulting in emissions reduction through energy savings.
  • Implemented the Zero Discharge Project at Architectural Coatings facilities in the U.S. and Canada, enabling PPG to recycle and reuse more than 1.7 million gallons of water in its manufacturing process over the past two years.
  • Installed a combined heat and power (CHP) unit at the Caivano, Italy, facility, creating an efficiency improvement equating to an annual reduction of approximately 1,100 metric tons of carbon dioxide (CO2 ).
  • Invested more than $8.7 million between 2015 and 2021 in PPG’s global COLORFUL COMMUNITIES® initiative.

In 2021, PPG reduced process waste, increased renewable energy use in its facilities and increased sales from sustainably advantaged products. Highlights include:

  • 38% of sales from sustainably advantaged products against the goal of 40% by 2025;
  • 24% of electricity usage from renewable energy sources against the goal of 25% by 2025;
  • 40% of manufacturing and research and development facilities with zero process waste to landfill, above the goal of 35% by 2025; and
  • 37% reduction in waste disposal intensity from the 2017 baseline, above the goal of 25% by 2025.

To create strong and equitable communities, PPG worked to engage employees and diversify its recruiting and talent pools. Efforts focused on diversity, equity and inclusion (DE&I) include:

  • Unveiled new DE&I commitments:
    • Achieve 34% to 36% representation of non-frontline global female professionals by 2025. PPG achieved 30% as of December 31, 2021.
    • Increase representation of Black, Latino and Asian employees by 45% to 55% across our non-frontline, U.S.-based employee population (using January 1, 2021, as our baseline). At the end of 2021, PPG increased non-frontline Black employees by 13%, Latino employees by 9% and Asian employees by 8%.
    • Achieve total global employee resource network (ERN) and DE&I capability-building participation of 50% by 2025. As of the end of 2021, PPG achieved 33% of this goal.
  • Published the first PPG DE&I Report .
  • Grew eight global ERNs to include more than 7,000 employee members across more than 60 countries.
  • Invested $7.4 million through 2021 to advance racial equity in the U.S. by funding educational pathways for Black communities and people of color.

PPG’s 2021 reporting disclosures align with the Global Reporting Initiative (GRI) Standards and the Sustainability Accounting Standards Board (SASB) chemical standard. The company also strengthened its reporting against the United Nations Sustainable Development Goals (UN SDGs) and reported qualitative climate-related risks according to the Task Force on Climate-Related Financial Disclosures (TCFD).

To learn more about ESG at PPG and explore the report, visit sustainability.ppg.com .

PPG: WE PROTECT AND BEAUTIFY THE WORLD™

At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for nearly 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 75 countries and reported net sales of $16.8 billion in 2021. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com .

We protect and beautify the world and ErgoLuxe are trademarks and Colorful Communities and the PPG Logo are registered trademarks of PPG Industries Ohio, Inc.

Comex is a registered trademark of Consorcio Comex, S.A. de C.V.

CATEGORY Sustainability

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye